Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keryx Biopharmaceuticals Inc.

Division of Akebia Therapeutics Inc.

Latest From Keryx Biopharmaceuticals Inc.

Ardelyx Plans Mid-2020 NDA Filing For Tenapanor In Hyperphosphatemia

The company reported positive Phase III data from a second trial testing the first-in-class therapy as monotherapy for managing hyperphosphatemia in patients on dialysis.

Financing Business Strategies

Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack

Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.

Deals Commercial

Akebia And Keryx To Merge, Establishing Critical Mass In Renal Disease

Planned all-stock transaction would bring together Akebia’s R&D organization and Keryx’s commercial apparatus for Auryxia. That drug and Akebia’s Phase III vadadustat would create a complementary franchise, CEO Butler asserts.

Deals Renal

Roxadustat To Overtake Epogen In Treating Anemia In CKD By 2021

The market for the treatment of anemia in chronic kidney disease will see Epogen eroded by biosimilars before the overall segment finally returns to growth following the launch of HIF-PHI inhibitor roxadustat, according to Datamonitor Healthcare's latest forecast.

Renal Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Renal System
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Akebia Therapeutics Inc.
  • Senior Management
  • Jodie Morrison, Interim CEO
    Scott A Holmes, CFO
    John F Neylan, MD, CMO
    Melissa Bradford-Klug, CBO
  • Contact Info
  • Keryx Biopharmaceuticals Inc.
    Phone: (617) 466-3500
    One Marina Park Dr.
    12th Fl.
    Boston, MA 02210